Management of Alcohol Withdrawal in Pregnant Women

Primary Treatment Approach

The European Association for the Study of Liver explicitly states that alcohol withdrawal syndrome should be treated with benzodiazepines, recognizing that untreated alcohol withdrawal poses greater maternal and fetal risks than medication exposure, according to the European Association for the Study of Liver 1, 2
Benzodiazepines are the recommended pharmacologic treatment for alcohol withdrawal syndrome in pregnancy, as stated by the European Association for the Study of Liver 1, 2

Untreated alcohol withdrawal can be fatal to both mother and fetus, making intervention medically necessary despite pregnancy, as reported by the Journal of Hepatology 1, 2
Alcohol use during pregnancy causes preterm birth, small for gestational age infants, fetal alcohol spectrum disorder, and fetal alcohol syndrome—all causing permanent impairments, according to the Journal of Hepatology 1, 2, 3

All pregnant women should undergo universal screening for alcohol use using validated instruments, as recommended by the American College of Obstetricians and Gynecologists 4
The TWEAK or T-ACE screening tools should be used specifically to detect lower-level consumption in pregnant women, according to the American College of Obstetricians and Gynecologists 4
The AUDIT questionnaire should be used to assess quantity, frequency, heavy episodic drinking, and behavioral manifestations in those screening positive, as stated by the World Health Organization 1, 2, 3

Psychosocial treatment is the primary intervention for alcohol use disorder in pregnancy and should be initiated immediately upon identification, as recommended by the American College of Obstetricians and Gynecologists 1, 2, 5
Brief multicomponent interventions using the FRAMES framework effectively reduce alcohol consumption and increase abstinence rates, according to the American College of Obstetricians and Gynecologists 4

Naltrexone or acamprosate may be used when psychosocial interventions have failed and continued alcohol exposure outweighs theoretical medication risks, as stated by the American College of Obstetricians and Gynecologists 1, 2, 5
Disulfiram is absolutely contraindicated in pregnancy due to association with fetal abnormalities, according to the American College of Obstetricians and Gynecologists 1, 2, 5
Baclofen should be used with extreme caution as it may accumulate and cause neonatal withdrawal syndrome, as reported by the American College of Obstetricians and Gynecologists 1, 5

Never withhold benzodiazepines for alcohol withdrawal treatment solely due to pregnancy status—untreated withdrawal poses greater risk, as stated by the American College of Obstetricians and Gynecologists 1, 2
Never use disulfiram under any circumstances in pregnancy, according to the American College of Obstetricians and Gynecologists 1, 2, 5
Do not recommend acute detoxification or attempting to wean alcohol before delivery for most women, as acute maternal withdrawal and relapse can be harmful or fatal to both mother and fetus, as reported by the American Journal of Obstetrics and Gynecology 6, 7

All pregnant women must be advised to abstain completely from alcohol, as no safe threshold of consumption during pregnancy has been established, according to the American College of Obstetricians and Gynecologists 4, 8, 9, 10

The European Association for the Study of Liver states that benzodiazepines are the gold standard treatment for alcohol withdrawal syndrome, and the risks of untreated withdrawal outweigh medication exposure risks in pregnant women 11
Symptom-triggered dosing with lorazepam is recommended to minimize total benzodiazepine exposure, with assessment of withdrawal severity using CIWA-Ar score, treating if score >8 (moderate withdrawal) or ≥15 (severe withdrawal) 11
Lorazepam is preferred over chlordiazepoxide due to its predictable pharmacokinetics, which allows for titration to effect without risk of delayed, profound sedation from accumulated metabolites 11

Monitor for neonatal withdrawal syndrome if benzodiazepines are used near delivery, with chlordiazepoxide withdrawal in neonates having a delayed onset (up to day 21), making lorazepam's shorter half-life and lack of active metabolites advantageous 12

Chlordiazepoxide can produce delayed neonatal withdrawal, with symptoms appearing up to 21 days after birth, whereas lorazepam’s shorter half‑life leads to a more predictable and earlier onset of any withdrawal, facilitating timely monitoring. 13

Infants exposed to benzodiazepines in utero may develop withdrawal signs such as irritability, tremors, hyperreflexia, excessive crying, and feeding difficulties; the onset can occur from a few days to several weeks after delivery. [14][13]
Withdrawal associated with chlordiazepine exposure may begin as late as 21 days post‑natally and persist for up to 9 months, reflecting the drug’s active metabolites and prolonged elimination in the newborn. 13

Neonatal monitoring for withdrawal syndrome is advised whenever benzodiazepines are administered near delivery, regardless of the specific agent used. 13